Changeflow GovPing Pharma & Healthcare High-flow Nasal Cannula Versus Conventional Oxy...
Routine Notice Added Final

High-flow Nasal Cannula Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema

Favicon for changeflow.com ClinicalTrials.gov Studies
Detected
Email

Summary

NIH has registered Clinical Trial NCT07536477, a randomized controlled study evaluating High-flow Nasal Cannula Oxygen Therapy (HFNC) versus Conventional Oxygen Therapy (COT) in patients with High-Altitude Pulmonary Edema (HAPE). The single-center trial plans to enroll 168 participants, with an estimated completion date of April 17, 2026. HFNC is the sole intervention under investigation.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document records the registration of Clinical Trial NCT07536477 on ClinicalTrials.gov, describing a randomized study comparing High-flow Nasal Cannula Oxygen Therapy to conventional oxygen support for treating High-Altitude Pulmonary Edema. The trial specifies conditions (HAPE), interventions (HFNC), and participant count but does not establish new regulatory requirements.

Healthcare providers and medical device manufacturers involved in respiratory therapy should note this clinical investigation of HFNC efficacy for altitude-related pulmonary edema. While this registration does not impose compliance obligations, it reflects ongoing evaluation of oxygen delivery technologies that may inform future clinical practice guidelines and device submissions.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema

N/A NCT07536477 Kind: NA Apr 17, 2026

Abstract

This study aims to evaluate whether High-flow Nasal Cannula Oxygen Therapy (HFNC) provides superior respiratory support compared to Conventional Oxygen Therapy (COT) in patients with High-Altitude Pulmonary Edema (HAPE).

Conditions: High-altitude Pulmonary Edema

Interventions: High-flow Nasal Cannula Oxygen Therapy (HFNC)

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536477

Who this affects

Applies to
Healthcare providers Medical device makers
Industry sector
3345 Medical Device Manufacturing 6211 Healthcare Providers
Activity scope
Clinical trial registration Respiratory therapy research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Public Health Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!